RxDoctor Payments Data

Tonya Ditrapani Stephenson, MD

Neurology · Venice, FLNPI 1093754863

Payments from drug & device makers

$6,117in general payments, 2019–2025

Across 329 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$901
  • Novartis$513
  • Neurocrine Biosciences, Inc.$279
  • Biogen$270
  • Lundbeck LLC$258
  • EMD Serono, Inc.$248
  • plus $4K from 38 others

What the payments were for

  • Speaking & faculty fees$1092%
  • Food & beverage$5,88396%
  • Education$1252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,117 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$259,352
Medicare patients
551
Services billed
7,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4630$708,606
VyvgartEfgartigimod Alfa-Fcab11$630,458
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5023$543,610
Nurtec OdtRimegepant Sulfate47$88,780
AustedoDeutetrabenazine12$50,469
QuliptaAtogepant37$40,226
UbrelvyUbrogepant20$24,605
Dalfampridine ErDalfampridine23$16,741
Aimovig AutoinjectorErenumab-Aooe21$15,680
Lacosamide82$8,301
LamictalLamotrigine11$7,236
Pyridostigmine Bromide ErPyridostigmine Bromide14$7,192
Pramipexole ErPramipexole Di-Hcl11$5,878
Gabapentin329$5,588
Memantine Hcl215$5,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$156$630,45811 claims
PfizerNurtec Odt$193$88,78047 claims
AbbVieQulipta, Ubrelvy$901$64,83057 claims
Teva Pharmaceuticals USA, Inc.Austedo$184$50,46912 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$71$4,11539 claims
Upsher-smith Laboratories LLCTopiramate$53$1,93661 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,434 neurology providers in Florida.

Other neurology in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →